Objective To observe the value of digital subtraction angiography(DSA)iFlow parameters for predicting major amputation in patients with acute lower limb ischemia(ALLI)within 30 days after revascularization operation.Methods Totally 310 ALLI patients who underwent revascularization operation were retrospectively included and divided into major amputation group(n=36)and non-major amputation group(n=274)according to major amputation within 30 days after revascularization operation or not.iFlow parameters,including time to peak(TTP)and the Peak were obtained after processing of DSA images after revascularization.Receiver operating characteristic(ROC)curves were used to screen the optimal cut-off value of TTP and Peak for predicting major amputation post operation,and then TTP and Peak were dichotomized.The dichotomized TTP and Peak variables and other variables were admitted into a multivariate logistic regression to identify independent predictors of major amputation.Results TTP was higher and Peak was lower in major amputation group than those in non-major amputation group(both P＜0.05).ROC curve analysis showed that the area under the curve(AUC)of TTP and Peak for predicting major amputation within 30 days post operation was 0.831 and 0.712,respectively,and the optimal cut-off value was 16 s and 1.53,respectively.Multivariate logistic regression analysis revealed that atrial fibrillation(AF)[OR(95％CI)=3.048(1.076,8.632)],livid skin appearance[OR(95％CI)=6.035(2.323,15.677)],TTP≥16 s after revascularization operation[OR(95％CI)=8.414(3.116,22.723)]and high myoglobin levels measured 48 h after operation[OR(95％CI)=1.001(1.001,1.001)]were all independent predictors of major amputation within 30 days in ALLI patients,but dichotomized Peak variable was not an independent predictor[OR(95％CI)=0.485(0.183,1.283),P=0.145].Conclusion TTP obtained through DSA iFlow was valuable for predicting major amputation in ALLI patients within 30 days after revascularization operation.

After being treated with acupuncture, some patients with idiopathic tinnitus may experience a short-term aggravation of tinnitus symptoms on the original basis. These symptoms can be gradually relieved and the overall condition fluctuates towards recovery. This phenomenon has brought some difficulties to patients and clinicians. Based on the academic view of TCM, "destroying pathogens and re-building balance", and in association with the existing understanding of acupuncture in modern medicine for tinnitus, this paper briefly discusses the mechanism and influencing factors of symptom fluctuation in patients with idiopathic tinnitus after acupuncture treatment in terms of both TCM and modern medicine, and proposes the future direction in the research of symptom fluctuation, so as to promote the recognition of clinicians and patients on symptom fluctuation and make rational use of its positive effects. Besides, it is hoped that more researchers will pay attention to symptom fluctuation and advance the exploration of it in academic field.
Humans ; Tinnitus/physiopathology* ; Acupuncture Therapy ; Male ; Female

Objective To observe the characteristics of gut microbiota in patients with type 2 diabetes mellitus(T2DM)with different traditional Chinese medicine(TCM)syndrome types,and to further explore the key microbial communities and functional differences affecting syndrome differentiation.Methods A total of 45 patients who visited the Department of Geriatrics,Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine in 2023 were enrolled.These included 15 T2DM patients with qi-yin deficiency and blood stasis syndrome(Group A),15 T2DM patients with qi-yin deficiency syndrome(Group B),and 15 non-diabetic patients from the same period(Group C).Fecal samples were collected,and 16S rRNA sequencing and analysis were performed.Results 1)A total of 1 564 operational taxonomic units(OTUs)were obtained from the three groups of patients,with 224,127,and 351 unique OTUs identified in Groups A,B and C,respectively.2)Both α-and β-diversity analyses indicated differences among the gut microbiota of the three groups.For instance,in the α-diversity analysis,the Sobs index showed significant inter-group differences(P＜0.01).Group A(264.00±88.84)was significantly higher than Group B(145.90±87.0)(P＜0.01),while Group B was significantly lower than Group C(229.7±112.4)(P＜0.05).In the β-diversity analysis,the principal coordinate analysis(PCoA)indicated a clear separation among groups(R=0.1610,P＜0.01).The R values in the Anosim/Adonis analysis ranged from 0.144 to 0.196,and the R2 values ranged from 0.067 to 0.083,all indicating differences in inter-group comparisons(P＜0.01).3)At the phylum level,Firmicutes,Actinobacteriota,and Bacteroidota were predominant in all groups.Among them,Bacteroidota exhibited significant inter-group differences(P＜0.05),with its abundance in Group A being significantly higher than that in Group B(P＜0.01).4)Analysis of differences in microbiota composition,combined with linear discriminant analysis effect size(LEfSe)and Random Forest analysis,revealed that,at the genus level,the microbiota biomarkers between Group A and Group B were Parabacteroides,Bacteroides,g_unclassified_f_Lachnospiraceae,Roseburia,and Aspergillus,those between Group B and Group C were Erysipelotrichaceae_UCG-003 and Ruminococcus,and those between Group A and Group C were Parabacteroides,Anaerotruncus,and Oscillibacter.The results were validated by receiver operating characteristic(ROC)curve analysis,which suggested that the microbiota biomarkers between Group A and Group B(AUC=0.91;95％CI,0.80-1.00),Group B and Group C(AUC=0.84;95％CI,0.69-0.99),Group A and Group C(AUC=0.87;95％CI,0.75-0.99)had good diagnostic efficacy.5)The study identified 116 major pathways with inter-group differences through Kyoto Encyclopedia of Genes and Genomes(KEGG)analysis.For example,the enrichment degree of ABC transporter pathway in Group A(2.58±0.36)was significantly lower than those in Group B(2.90±0.48)and Group C(3.11±0.66)(P＜0.05).These pathways were associated with metabolism and environmental information processing.g.Conclusion The differences in the gut microbiota characteristics and functions among patients with specific TCM syndromes of T2DM may provide references for TCM syndrome differentiation and therapeutic mechanisms.

Objective To observe the value of digital subtraction angiography(DSA)iFlow parameters for predicting major amputation in patients with acute lower limb ischemia(ALLI)within 30 days after revascularization operation.Methods Totally 310 ALLI patients who underwent revascularization operation were retrospectively included and divided into major amputation group(n=36)and non-major amputation group(n=274)according to major amputation within 30 days after revascularization operation or not.iFlow parameters,including time to peak(TTP)and the Peak were obtained after processing of DSA images after revascularization.Receiver operating characteristic(ROC)curves were used to screen the optimal cut-off value of TTP and Peak for predicting major amputation post operation,and then TTP and Peak were dichotomized.The dichotomized TTP and Peak variables and other variables were admitted into a multivariate logistic regression to identify independent predictors of major amputation.Results TTP was higher and Peak was lower in major amputation group than those in non-major amputation group(both P＜0.05).ROC curve analysis showed that the area under the curve(AUC)of TTP and Peak for predicting major amputation within 30 days post operation was 0.831 and 0.712,respectively,and the optimal cut-off value was 16 s and 1.53,respectively.Multivariate logistic regression analysis revealed that atrial fibrillation(AF)[OR(95％CI)=3.048(1.076,8.632)],livid skin appearance[OR(95％CI)=6.035(2.323,15.677)],TTP≥16 s after revascularization operation[OR(95％CI)=8.414(3.116,22.723)]and high myoglobin levels measured 48 h after operation[OR(95％CI)=1.001(1.001,1.001)]were all independent predictors of major amputation within 30 days in ALLI patients,but dichotomized Peak variable was not an independent predictor[OR(95％CI)=0.485(0.183,1.283),P=0.145].Conclusion TTP obtained through DSA iFlow was valuable for predicting major amputation in ALLI patients within 30 days after revascularization operation.

Although social cognitive impairment is commonly observed in patients with schizophrenia, how to effectively assess it and the clinical value of such evaluations warrant further discussion. In 2022, the release of the "European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia" provided guidance for research and clinical practices in this field. This article aims to analyze the necessity, effectiveness, and feasibility of conducting assessments in clinical settings based on the recommended approaches outlined in the guidance, considering the current clinical landscape in China.

Although cognitive impairment is considered a core symptom of schizophrenia and significantly impacts functional outcomes, it is often overlooked in clinical practice. The European Psychiatric Association released “Guideline on Assessment of Cognitive Impairment in Schizophrenia” in 2022, providing recommendations for research and clinical practice. This paper interprets the neurocognitive aspects of schizophrenia covered in the guidelines, introduces neurocognitive assessment tools used in China and their application settings, examines the relationship between subjective and objective assessments of cognitive impairment, and briefly discusses the connections between neurocognition and positive and negative symptoms. The paper also considers the future development of neurocognitive assessment tools in China.

Cognitive impairment in schizophrenia emerges early and persists, is a core symptom that severely affects social functioning. In 2022, the European Psychiatric Association published the " European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia", presenting the latest evidence and systematic review results. The guidance recommends comprehensive and detailed cognitive assessments for all individuals with schizophrenia, emphasizing the phase of early intervention. In conjunction with the recommendations of the guidance and the current state of research both domestically and internationally, this article provides an overview of cognitive impairment in schizophrenia, including definition, impact, selection of assessment tools, and limitations of cognitive assessments. It also connects with clinical practice in China, outlining the development and shortcomings of cognitive assessments for schizophrenia. It is suggested that a clinically simple questionnaire suitable for the Chinese population is needed to help physicians quickly identify cognitive impairment.

Cognitive impairment is one of the core features of schizophrenia and severely affects the prognosis of the disorder. Improving cognitive impairment is of great significance for alleviating symptoms, preventing relapses, enhancing the quality of life, and reducing the social burden in patients with schizophrenia. Based on the "Guidelines for the Assessment of Cognitive Impairment in Schizophrenia" published by the European Psychiatric Association in 2022, the article focuses on the intervention and management of cognitive impairment in schizophrenia patients following a systematic assessment, while also considering the specific context of practice in China. This paper reviews recent progress in cognitive impairment interventions for schizophrenia, providing clinical guidance across three key aspects: pharmacotherapy, physical therapy, and psychotherapy. Other interventions are also discussed. Additionally, it addresses the existing challenges and unresolved issues, aiming to provide a basis for decision-making in the current treatment of cognitive impairment in schizophrenia.

Although social cognitive impairment is commonly observed in patients with schizophrenia, how to effectively assess it and the clinical value of such evaluations warrant further discussion. In 2022, the release of the "European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia" provided guidance for research and clinical practices in this field. This article aims to analyze the necessity, effectiveness, and feasibility of conducting assessments in clinical settings based on the recommended approaches outlined in the guidance, considering the current clinical landscape in China.

Although cognitive impairment is considered a core symptom of schizophrenia and significantly impacts functional outcomes, it is often overlooked in clinical practice. The European Psychiatric Association released “Guideline on Assessment of Cognitive Impairment in Schizophrenia” in 2022, providing recommendations for research and clinical practice. This paper interprets the neurocognitive aspects of schizophrenia covered in the guidelines, introduces neurocognitive assessment tools used in China and their application settings, examines the relationship between subjective and objective assessments of cognitive impairment, and briefly discusses the connections between neurocognition and positive and negative symptoms. The paper also considers the future development of neurocognitive assessment tools in China.